Scientists at Stanford have created a non-invasive ultrasound method of brain cleansing that boosted the survival rate of mice after stroke by activating natural detoxification mechanisms. The technology, accidentally discovered during experiments with the blood-brain barrier, stimulates microglial immune cells to dispose of toxic waste and improves the circulation of cerebrospinal fluid. The method opens the way to treating the consequences of strokes and injuries without drugs.
A non-invasive, drug-free ultrasound method helps cleanse the brain and reduce inflammation, potentially offering a radically simple new approach to treating neurological diseases.
This herculean effort could help scientists unravel the causes of neurodevelopmental disorders. In one study, led by Arnold Kriegstein at the University of California, San Francisco, scientists found brain stem cells that are potentially co-opted to form a deadly brain cancer in adulthood. Other studies shed light on imbalances between excitatory and inhibitory neurons—these ramp up or tone down brain activity, respectively—which could contribute to autism and schizophrenia.
“Many brain diseases begin during different stages of development, but until now we haven’t had a comprehensive roadmap for simply understanding healthy brain development,” said Kriegstein in a press release. “Our map highlights the genetic programs behind the growth of the human brain that go awry during specific forms of brain dysfunction.”
Over a century ago, the first neuroscientists used brain cell shapes to categorize their identities. BICAN collaborators have a much larger arsenal of tools to map the brain’s cells.
Degenerative joint diseases like osteoarthritis and intervertebral disk degeneration are conditions that affect millions of people worldwide, leading to pain and reduced mobility. These diseases remain incurable because current treatments manage symptoms rather than addressing the root cause.
A Yale study published in the journal Bone Research found that cytosolic phospholipase A2 (cPLA2) is an important enzyme. It plays a key role in inflammation and cartilage breakdown. The study suggests that cPLA2 could be a possible target for treating joint diseases.
Researchers have uncovered and then overcome an obstacle that has led to the failure of pioneering efforts in xenotransplantation, in which an animal kidney is transplanted into a human.
More than 800,000 Americans have late-stage kidney disease, yet only 3% receive a transplant each year, according to the U.S. Centers for Disease Control and Prevention. To boost the supply of available organs, experts are exploring the use of genetically modified pig kidneys.
The genetic changes are meant to keep the human immune system from recognizing the animal organ as foreign and attacking it to cause rejection. However, recipients’ immune reactions can still lead to organ damage and failure after the surgery.
Humanity’s future is now framed by artificial intelligence (AI) and increasing interventions in the human body to cure and to enhance, i.e., transhumanism. Considering the stakes and the dangers, a philosophical perspective is imperative.
Make a tax-deductible donation of any amount to help support Closer To Truth continue making content like this: https://shorturl.at/OnyRq.
Terrence William Deacon is an American neuroanthropologist. He taught at Harvard for eight years, relocated to Boston University in 1992, and is currently Professor of Anthropology and member of the Cognitive Science Faculty at the University of California, Berkeley.
Paul Thagard is Distinguished Professor Emeritus of Philosophy at the University of Waterloo and a Fellow of the Royal Society of Canada, the Cognitive Science Society, and the Association for Psychological Science. His work focuses on cognitive science, philosophy of mind, and the philosophy of science and medicine.
A team of neuroscientists has uncovered evidence that genetic influences on intelligence may operate through the density of brain wiring, highlighting a potential biological bridge between inherited DNA differences and the brain structures that support reasoning and problem-solving.
Visionary, patient-centric health research for all — dr. julia moore vogel, phd — scripps research / long covid treatment trial.
Dr. Julia Moore Vogel, PhD, MBA is Assistant Professor and Senior Program Director at The Scripps Research Institute (https://www.scripps.edu/science-and-me… where she is responsible for managing a broad portfolio of patient-centric health research studies, including The Long COVID Treatment Trial (https://longcovid.scripps.edu/locitt-t/), a fully remote, randomized, placebo-controlled clinical trial targeting individuals with long COVID, testing whether the drug Tirzepatide can reduce or alleviate symptoms of long COVID.
Prior to this current role, Dr. Vogel managed The Participant Center (TPC) for the NIH All of Us Research Program (https://www.scripps.edu/science-and-me… which was charged with recruiting and retaining 350,000 individuals that represent the diversity of the United States. TPC aims to make it possible for interested individuals anywhere in the US to become active participants, for example by collaborating with numerous outreach partners to raise awareness, collecting biosamples nationwide, returning participants’ results and developing self-guided workflows that enable participants to join whenever is convenient for them.
Prior to joining the Scripps Research Translational Institute, Dr. Vogel created, proposed, fundraised for, and implemented research and clinical genomics initiatives at the New York Genome Center and The Rockefeller University. She oversaw the proposal and execution of grants, including a $44M NIH Center for Common Disease Genomics in collaboration with over 20 scientific contributors across seven institutions. She also managed corporate partnerships, including one with IBM that assessed the relative value of several genomic assays for cancer patients.
Dr. Vogel has a BS in Mathematics from Rensselaer Polytechnic Institute, a PhD in Computational Biology and Medicine from Cornell and an MBA from Cornell.
Polygenic risk scores estimate genetic predisposition to complex diseases by combining thousands of DNA variants. Dr. Anna CF Lewis of Harvard Medical School discusses their promise for personalized medicine and the ethical challenges they raise.
